AI Leaders Urge Nucleic Acid Screening for Bioweapon Prevention

AI leaders, biotech executives, and biosecurity specialists are urging U.S. lawmakers to require screening for purchases of synthetic nucleic acids and the machines that produce them. A coalition of nearly 75 leaders believes AI is lowering the "know-how barrier," allowing individuals without advanced training to perform complex lab methods. The group argues a federal requirement would close a gap in the biotech supply chain. They note that advanced AI systems can now answer specialized lab-method questions at a high level. While near-term risks are mixed, the group warns the historical know-how barrier for bad actors could shrink. Their proposal would obligate DNA synthesis providers and equipment makers to review orders for concerning sequences and confirm customer legitimacy. Many large providers already conduct voluntary checks. The signers call for Congress to create a consistent national standard this session, rather than a "patchwork of conflicting laws." This collective action highlights a rare moment of agreement among often-opposing stakeholders. This matters because it addresses potential biosecurity risks in an evolving technological landscape.